Literature DB >> 22733609

When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!

Philip M Grant1, Andrew R Zolopa.   

Abstract

Despite the substantial benefits of combination antiretroviral therapy (ART), a significant proportion of HIV-infected individuals still present with advanced disease and active AIDS-related opportunistic infections (OIs). The weight of evidence from recent studies supports the early initiation of ART (ie, within 2 weeks of initiating treatment for the acute OIs). Initiating ART early in acutely ill patients can reduce AIDS-related progression and death. Early ART has not been associated with increased rates of immune reconstitution inflammatory syndrome in prospective studies of non-tuberculosis OIs, although this concern is frequently cited as a reason to delay ART. Nor has early ART been associated with increased adverse outcomes. Nonetheless, initiating ART early in acute care settings can be challenging to implement and requires a well-coordinated multidisciplinary team with expertise in ART management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733609     DOI: 10.1007/s11904-012-0126-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  38 in total

1.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.

Authors:  B J Park; S Shetty; A Ahlquist; A Greenbaum; J L Miller; A Motsi; K McCarthy; N Govender
Journal:  Int J STD AIDS       Date:  2011-04       Impact factor: 1.359

3.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

4.  Integration of antiretroviral therapy with tuberculosis treatment.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew L Gray; Tanuja Gengiah; Santhanalakshmi Gengiah; Anushka Naidoo; Niraksha Jithoo; Gonasagrie Nair; Wafaa M El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

5.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

6.  Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Authors:  Paul E Sax; Caroline E Sloan; Bruce R Schackman; Philip M Grant; Jian Rong; Andrew R Zolopa; William Powderly; Elena Losina; Kenneth A Freedberg
Journal:  HIV Clin Trials       Date:  2010 Sep-Oct

7.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

Review 8.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

9.  High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.

Authors:  Tihana Bicanic; Robin Wood; Graeme Meintjes; Kevin Rebe; Annemarie Brouwer; Angela Loyse; Linda-Gail Bekker; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  10 in total

1.  A Minority of Patients Newly Diagnosed with AIDS Are Started on Antiretroviral Therapy at the Time of Diagnosis in a Large Public Hospital in the Southeastern United States.

Authors:  Neela D Goswami; Jonathan Colasanti; Jonathan J Khoubian; Yijian Huang; Wendy S Armstrong; Carlos Del Rio
Journal:  J Int Assoc Provid AIDS Care       Date:  2017-02-15

2.  Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable.

Authors:  Ank E Nijhawan; Ellen Kitchell; Sarah Shelby Etherton; Piper Duarte; Ethan A Halm; Mamta K Jain
Journal:  AIDS Patient Care STDS       Date:  2015-07-08       Impact factor: 5.078

3.  A paradoxical decline: intracranial lesions in two HIV-positive patients recovering from cryptococcal meningitis.

Authors:  Kenneth D Pettersen; Peter G Pappas; Peter Chin-Hong; Sanjiv M Baxi
Journal:  BMJ Case Rep       Date:  2015-10-16

4.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

5.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Authors:  David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes
Journal:  N Engl J Med       Date:  2014-06-26       Impact factor: 91.245

Review 6.  Critical care of persons infected with the human immunodeficiency virus.

Authors:  Anuradha Ganesan; Henry Masur
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 7.  Urological aspects of HIV and AIDS.

Authors:  Chris F Heyns; Shaun G Smit; André van der Merwe; Amir D Zarrabi
Journal:  Nat Rev Urol       Date:  2013-10-29       Impact factor: 14.432

Review 8.  HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease.

Authors:  José Ernesto Vidal
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

9.  A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.

Authors:  Yan-Ming Zeng; Yao Li; Xiao-Qing He; Yin-Qiu Huang; Min Liu; Jing Yuan; Yan Bai; Yan-Qiu Lu; Huan Li; Yao-Kai Chen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

10.  HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study.

Authors:  Vanessa Nicolau; Rui Cortes; Maria Lopes; Ana Virgolino; Osvaldo Santos; António Martins; Nancy Faria; Ana Paula Reis; Catarina Santos; Fernando Maltez; Álvaro Ayres Pereira; Francisco Antunes
Journal:  Healthcare (Basel)       Date:  2021-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.